AP536A - Oral liquid compositions containing paroxetine resinate - Google Patents
Oral liquid compositions containing paroxetine resinate Download PDFInfo
- Publication number
- AP536A AP536A APAP/P/1995/000715A AP9500715A AP536A AP 536 A AP536 A AP 536A AP 9500715 A AP9500715 A AP 9500715A AP 536 A AP536 A AP 536A
- Authority
- AP
- ARIPO
- Prior art keywords
- paroxetine
- pharmaceutical composition
- oral liquid
- depression
- composition according
- Prior art date
Links
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims description 31
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title claims description 27
- 229960002296 paroxetine Drugs 0.000 title claims description 27
- 239000007788 liquid Substances 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 title claims description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000005342 ion exchange Methods 0.000 claims abstract 2
- 239000012669 liquid formulation Substances 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract 2
- 229920001429 chelating resin Polymers 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 7
- 239000002518 antifoaming agent Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000032841 Bulimia Diseases 0.000 claims description 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 206010041250 Social phobia Diseases 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 239000006172 buffering agent Substances 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000000484 premenstrual tension Diseases 0.000 claims description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 239000003456 ion exchange resin Substances 0.000 claims description 3
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 claims 1
- 239000011342 resin composition Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229960005183 paroxetine hydrochloride Drugs 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940051147 fd&c yellow no. 6 Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A palatable and bioavailable oral liquid formulation comprising a paroxetine-ion exchange resinate complex,methods of preparation and use as a pharmaceutical
Description
NOVEL FORMULATION
The present invention relates to novel formulations and to the use of such a formulation in the treatment and/or prevention of certain disorders.
US Patent 4,007,196 describes certain compounds which possess antidepressant activity. One specific compound mentioned in this patent is known as paroxetine and which has the following formula:
F
H
This compound has been approved for human use and is being sold in many countries around the world as an anti-depressant agent
All paroxetine sold to date has been in the form of oral swallow tablets.
Many physicians have expressed a desire to be able to prescribe an oral liquid containing paroxetine and some have even made their own oral liquid by crushing conventional swallow tablets and mixing them with water. There are however, a number of draw-backs to this oral liquid, firstly paroxetine has a very bitter taste which is highly noticeable when administered as an oral liquid, secondly such oral liquids have poor stability qualities and have a shelf-life of only a few days.
WO 91/13612 relates to the sustained release of pharmaceuticals using compositions in which the drug is complexed with an ion-exchange resin. The specific ion-exchange resin described in this published patent application is Amberlite IRP-69.
When Amberlite IRP-69 is used to complex with paroxetine it was found that whilst the taste was effectively masked the composition had an unacceptably low bioavailability when compared to a swallow tablet.
It has now been found that Amberlite IRP-88 can be used to form a stable taste masted complex with paroxetine and which complex has acceptable bioavailability when compared to the conventional swallow tablet.
Accordingly, the present invention provides an oral liquid pharmaceutical composition comprising a paroxetine - Amberlite IRP-88 complex.
Amberlite IRP-88 is commercially available from Rohm & Haas in a pharmaceutically acceptable grade.------c~ c
c.
cr
The oral liquid pharmaceutical composition is prepared in conventional manner such as by mixing paroxetine and Amberlite IRP-88 together in an aqueous medium. Suitably the IRP-88 and paroxetine are present in a ratio of 1:1 to 2:1. It should be appreciated that superior taste masking properties are obtained with a 2:1 ratio.
Other pharmaceutically acceptable excipients may also be added such as thickeners such as Keltrol and/or Avicel (in particular Avicel CL 611); dispersants such as propylene glycol; moisture retaining agents such as glycerol; sweetners such as sorbitol and sodium saccharin buffering agents such as citric acid and sodium citrate; preservatives such as sodium benzoate and mixtures of methyl and and propyl parabens (parahydroxybenzoates), artificial colours such as F D and C Yellow No. 6 Sunset Yellow; flavouring such as Givaudan Natural Orange and/or Lemon; and antifoaming agents such as silicone anti-foam.
Preferably the amounts of buffering agents are controlled to give a pH of 4 to 6. Most preferably a pH of 4.5 to 6.0.
The amount of paroxetine used is adjusted such that in a single unit dose there is a therapeutically effective amount of paroxetine. Preferably the unit dose contains from 10 to 100 mg paroxetine (as measured in terms of the free base). More preferable the amount of paroxetine in a unit dose is lOmg, 20mg, 30mg, 40mg or
50mg. The most prefened amount of paroxetine in a unit dose is 20mg of paroxetine.
Preferably the volume of liquid in a unit dose is in the range 5 to 20ml most preferably 10ml.
Preferably paroxetine used in the formulation is in the form of the hydrocholide hemi-hydrate which may be prepared according to the procedures outlined in US Patent 4,721,723.
Suitable procedures for preparing paroxetine include those mentioned in US
Patents 4,009,196,4,902,801,4,861,893 and 5,039,803 and PCT/GB 93/00721.
It has been mentioned that paroxetine has particular utility in the treatment of depression, paroxetine may also be used in the treatment of mixed anxiety and depression, obsessive compulsive disorders, panic, pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia and the depression arising from premenstrual tension and adolescence.
The present invention therefore also provides a method of treating or preventing any of the above disorders which comprises administering an effective or prophylatic amount of an oral liquid pharmaceutical composition comprising a paroxetine-Amberlite IRP-88 complex to a sufferer in need thereof.
The present invention further provides the use of an oral liquid pharmaceutical composition comprising a paroxetine-Amberlite IRP-88 complex in the manufacture of a medicament for treating or preventing the above disorders.>
.
cc
C’ c
cr
AP.00536
The present invention yet further provides a pharmaceutical composition for use in the treatment or prevention of the above disorders which comprises a paroxetine-Amberlite IRP-88 complex admixed with a pharmaceutically acceptable carrier.
The following examples illustrate the present invention:
Example 1 (1:1) Ratio of Amberlite IRP-88 to paroxetine.
| • | mg/10 ml | |
| Paroxetine hydrochloride t | 22.8 | |
| Amberlite IRP 88 (< 63 pm) | 22.8 | |
| Keltrol | 40.0 | |
| Propylene Glycol | 350.0 | |
| Glycerol | 350.0 | |
| Sorbitol (70%) | 4000.0 | |
| Citric acid | 15.0 | |
| Sodium Citrate | 10.0 | |
| Sodium benzoate | 10.0 | |
| Sodium Saccharin | 5.0 | |
| Sunset Yellow | 0.5 | |
| Givaudan Natural Orange | 1.0 | |
| Givaudan Natural Lemon | 2.0 | |
| Antifoam Silicone | 20.0 | |
| Water | to | 10.0 · |
AP/Γ.' 9 5 / 0 0 7 1 5
Example 2 (2:1) Ratio of Amberlite IRP to paroxetine mg/lOml
Paroxetine hydrochloride (< 180 microns) Amberlite IRP 88 (< 200 mesh)
Avicel CL 611
Propylene Glycol
Glycerol
Sorbitol (70%)
Citric acid (anhydrous)
22.8
40.0*
300.0
500.0
500.0
4000.0
15.0
BAD ORIGINAL £
Sodium Citrate (dihydrate) 10.0
Methyl parahydroxybenzoate 20.0
Propyl parahydroxybenzoate 6.0
Sodium Saccharin 5.0
FD&C Yellow No. 6 0.9
Givaudan Natural Orange 74388-74 1.0 mcl
Givaudan Natural Lemon74940-74 2.0 mcl
Silicone Antifoam 1510 20.0
Water to 10.0 ♦ on an Anhydrous basis
Example 3 5
As above but 40.0 mg was replaced with 300 mg of Avicel CL 611.
Example 4
As above but 15 mg of Keltrol and 300 mg of Avicel CL 611 was used.--
Claims (4)
- CiaimcAP. Ο Ο 5 3 61. An oral liquid composition for sustained release of a pharmaceutical acceptable drug comprising a drug-resin composition tormed from a pharmaceutical active drug and an ion-exchange resin in which at least 30% by weight of resinate particles having a particle size below 35 pm characterized that the active drug is paroxetine.5.6.7.IC 8.9.
- 2. A process for preparing a pharmaceutical composition as defined in claim 1 which process comprises mixing paroxetine and Amberlite IRP-88 together in aqueous medium.
- 3. A process according to claim 2 in which the molar ratio of IRP 88 to paroxetine is 1:1 to 2:1.
- 4. A pharmaceutical composition according to claim 1 in which any one or more of the following is added; thickeners, dispersants, moisture retaining agents, sweeteners, buffering agents, preservatives, artificial colours, flavourings and anti-foaming agents.A pharmaceutical composition according to claim 4 in which the amount of buffering agents are controlled to give a pH of 4 to 6.A pharmaceutical composition according to any one of claims 1,4 or 5 which is in the form of a unit dose. , ;C 3*1A pharmaceutical composition according to claim 6 in which the amount of paroxetine in the unit dose is lOmg, 20mg, 30mg, 40mg, or 50mg.OA pharmaceutical composition according to claims 1 or 4 to 7 in which the paroxetine is in the form of the hydrochloride hemihydrate.A method of treating or preventing mixed anxiety and depression, obsessive compulsive disorders, panic, pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia and depression arising from pre-menstrual tension and adolescence which comprises administering an effective or prophylatic amount of an oral liquid pharmaceutical composition as defined in claim 1. According to any one of claims 1 and 4 to 8 to a sufferer in need thereof.10. The use of an oral liquid pharmaceutical composition as defined in claim 1 comprising a paroxetine-Amberlite IRP-88 complex in the manufacture of medicament for treating or preventing mixed anxiety and depression, obsessiveBAD ORIGINAL compulsive disorders, panic, pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia and depression arising from pre-menstrual tension and adolescence.11. A pharmaceutical composition as defined in claim 1 for use in the treatment or 5 prevention of anxiety and depression, obsessive compulsive disorders, panic, pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia and depression arising from pre-menstrual tension and adolescence.Dated this 1st Day of February 1995. ’ ''—·MONEY - TT- TKENBERG <OO-6BAD ORIGINALAP.00536ABS'ihACTA palatable and bioavaiiable oral liquid formulation comprising a paroxetine-ion exchange resinate complex, methods of preparation and use as a pharmaceutical.s I L 0 0 / 5 6 /d/dV
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9402029A GB9402029D0 (en) | 1994-02-03 | 1994-02-03 | Novel formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9500715A0 AP9500715A0 (en) | 1995-04-30 |
| AP536A true AP536A (en) | 1996-09-26 |
Family
ID=10749765
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1996/000839A AP611A (en) | 1994-02-03 | 1995-01-30 | Oral liquid compositions containing paroxetine resinate. |
| APAP/P/1995/000715A AP536A (en) | 1994-02-03 | 1995-02-01 | Oral liquid compositions containing paroxetine resinate |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1996/000839A AP611A (en) | 1994-02-03 | 1995-01-30 | Oral liquid compositions containing paroxetine resinate. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5811436A (en) |
| EP (1) | EP0742715B1 (en) |
| JP (1) | JP4445590B2 (en) |
| CN (1) | CN1074922C (en) |
| AP (2) | AP611A (en) |
| AT (1) | ATE178489T1 (en) |
| AU (1) | AU682091B2 (en) |
| BG (1) | BG62843B1 (en) |
| BR (1) | BR9507055A (en) |
| CA (1) | CA2182593A1 (en) |
| CZ (1) | CZ285128B6 (en) |
| DE (1) | DE69508924T2 (en) |
| DK (1) | DK0742715T3 (en) |
| DZ (1) | DZ1850A1 (en) |
| ES (1) | ES2129806T3 (en) |
| FI (1) | FI118205B (en) |
| GB (1) | GB9402029D0 (en) |
| GR (1) | GR3030131T3 (en) |
| HU (1) | HUT75941A (en) |
| IL (1) | IL112521A (en) |
| MA (1) | MA23441A1 (en) |
| MX (1) | MX9603203A (en) |
| MY (1) | MY113036A (en) |
| NO (1) | NO307954B1 (en) |
| NZ (1) | NZ278891A (en) |
| OA (1) | OA10446A (en) |
| PL (1) | PL178331B1 (en) |
| RO (1) | RO116342B1 (en) |
| RU (1) | RU2136281C1 (en) |
| SK (1) | SK281214B6 (en) |
| TW (1) | TW436296B (en) |
| WO (1) | WO1995020964A1 (en) |
| ZA (1) | ZA95776B (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548084B2 (en) * | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US6638948B1 (en) * | 1996-09-09 | 2003-10-28 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
| DE69704679T2 (en) | 1997-06-10 | 2001-09-13 | Synthon Bv | 4-PHENYLPIPERIDINE DERIVATIVES |
| US6699882B2 (en) | 1998-03-24 | 2004-03-02 | Smithkline Beecham P.L.C. | Paroxetine compositions |
| DK172860B1 (en) * | 1998-03-25 | 1999-08-16 | Pharmacosmos Holding As | Iron dextran compound for use as a component of a therapeutic agent for the prevention or treatment of iron man |
| CH689805A8 (en) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing it. |
| GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
| US6660298B1 (en) * | 2000-07-27 | 2003-12-09 | Pentech Pharmaceuticals, Inc. | Paroxetine tablets and capsules |
| US6720003B2 (en) | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
| EP1250937B1 (en) * | 2001-04-09 | 2009-05-13 | Rohm And Haas Company | Controlled dissolution of active ingredients |
| US20020176842A1 (en) * | 2001-04-09 | 2002-11-28 | Lyn Hughes | Extended release of active ingredients |
| US6906206B2 (en) * | 2001-04-30 | 2005-06-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene |
| DE60210308T2 (en) * | 2001-08-09 | 2006-11-30 | Smithkline Beecham P.L.C., Brentford | COMPOSITION CONTAINING PAROXETIN AND A PHARMACEUTICALLY COMPATIBLE SALT OF GLYCYRRIC ACID |
| GB0119467D0 (en) * | 2001-08-09 | 2001-10-03 | Smithkline Beecham Plc | Novel compound |
| US6939877B2 (en) * | 2002-09-12 | 2005-09-06 | Wyeth | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans |
| US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
| US20050266082A1 (en) * | 2004-05-26 | 2005-12-01 | Patel Satishkumar A | Preparation of stable paroxetine HC1 ER tablets using a melt granulation process |
| WO2006018318A1 (en) * | 2004-08-18 | 2006-02-23 | Synthon B.V. | Liquid paroxetine compositions |
| US20060039975A1 (en) * | 2004-08-20 | 2006-02-23 | Zalman Vilkov | Paroxetine formulations |
| KR100672184B1 (en) | 2004-09-21 | 2007-01-19 | 주식회사종근당 | Choline or Choline Derivative Salts of Paroxetine |
| US20070112031A1 (en) * | 2005-11-14 | 2007-05-17 | Gant Thomas G | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| CN102430122A (en) * | 2005-12-13 | 2012-05-02 | 量子高科（北京）研究院有限公司 | Fluoxetine hydrochloride orally disintegrating tablet and preparation method thereof |
| FR2912057B1 (en) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | PHARMACEUTICAL COMPOSITION COMPRISING SAREDUTANT AND A SELECTIVE SEROTONIN RECAPTURE INHIBITOR OR SEROTONIN / NOREPINEPHRINE RECAPTURE INHIBITOR |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
| US20100273822A1 (en) * | 2009-04-22 | 2010-10-28 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins |
| WO2010150219A1 (en) * | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof |
| US8187617B2 (en) * | 2009-09-11 | 2012-05-29 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments |
| CN102905706A (en) | 2010-05-19 | 2013-01-30 | 安斯泰来制药株式会社 | Pharmaceutical composition containing solifenacin |
| CN104027306A (en) * | 2014-06-25 | 2014-09-10 | 万特制药(海南)有限公司 | Paroxetine oral suspension and preparation method thereof |
| GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| CN104382870A (en) * | 2014-10-30 | 2015-03-04 | 万全万特制药江苏有限公司 | Compound containing polacrilin potassium-paroxetine |
| CN106309363A (en) * | 2016-09-24 | 2017-01-11 | 万特制药(海南)有限公司 | Paroxetine hydrochloride oral suspension and preparation method thereof |
| CN108926528A (en) * | 2017-05-25 | 2018-12-04 | 北京万全德众医药生物技术有限公司 | Liquid oral compositions containing Amisulpride resinate |
| EP3917523B1 (en) | 2019-02-01 | 2024-09-11 | University of South Carolina | Bicyclic pyridine compounds for use in treating cancer |
| CN113209017B (en) * | 2021-06-02 | 2023-06-20 | 上海美优制药有限公司 | A kind of paroxetine hydrochloride suspension and preparation method thereof |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| GB2636182A (en) | 2023-12-04 | 2025-06-11 | Novumgen Ltd | An orally disintegrating tablet of paroxetine and its process of preparation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4007196A (en) * | 1973-01-30 | 1977-02-08 | A/S Ferrosan | 4-Phenylpiperidine compounds |
| WO1991013612A1 (en) * | 1990-03-12 | 1991-09-19 | Beecham Group Plc | Composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3688827T2 (en) * | 1985-10-25 | 1994-03-31 | Beecham Group Plc | Piperidine derivative, its manufacture and its use as a medicine. |
| IT1246188B (en) * | 1990-07-27 | 1994-11-16 | Resa Farma | PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING INCREASED SPEED OF DISSOLUTION OF THE ACTIVE SUBSTANCE AND COMPOSITIONS OBTAINED. |
-
1994
- 1994-02-03 GB GB9402029A patent/GB9402029D0/en active Pending
-
1995
- 1995-01-27 MY MYPI95000223A patent/MY113036A/en unknown
- 1995-01-30 CA CA002182593A patent/CA2182593A1/en not_active Abandoned
- 1995-01-30 DE DE69508924T patent/DE69508924T2/en not_active Expired - Lifetime
- 1995-01-30 HU HU9602151A patent/HUT75941A/en unknown
- 1995-01-30 RO RO96-01580A patent/RO116342B1/en unknown
- 1995-01-30 DK DK95906998T patent/DK0742715T3/en active
- 1995-01-30 PL PL95315679A patent/PL178331B1/en not_active IP Right Cessation
- 1995-01-30 BR BR9507055A patent/BR9507055A/en not_active IP Right Cessation
- 1995-01-30 NZ NZ278891A patent/NZ278891A/en not_active IP Right Cessation
- 1995-01-30 CZ CZ962293A patent/CZ285128B6/en unknown
- 1995-01-30 AP APAP/P/1996/000839A patent/AP611A/en active
- 1995-01-30 EP EP95906998A patent/EP0742715B1/en not_active Expired - Lifetime
- 1995-01-30 CN CN95191483A patent/CN1074922C/en not_active Expired - Fee Related
- 1995-01-30 MX MX9603203A patent/MX9603203A/en unknown
- 1995-01-30 SK SK1004-96A patent/SK281214B6/en unknown
- 1995-01-30 ES ES95906998T patent/ES2129806T3/en not_active Expired - Lifetime
- 1995-01-30 RU RU96117470/14A patent/RU2136281C1/en not_active IP Right Cessation
- 1995-01-30 WO PCT/EP1995/000319 patent/WO1995020964A1/en not_active Ceased
- 1995-01-30 US US08/682,799 patent/US5811436A/en not_active Expired - Lifetime
- 1995-01-30 AU AU15368/95A patent/AU682091B2/en not_active Expired
- 1995-01-30 JP JP52037095A patent/JP4445590B2/en not_active Expired - Lifetime
- 1995-01-30 AT AT95906998T patent/ATE178489T1/en active
- 1995-02-01 DZ DZ950010A patent/DZ1850A1/en active
- 1995-02-01 AP APAP/P/1995/000715A patent/AP536A/en active
- 1995-02-01 MA MA23768A patent/MA23441A1/en unknown
- 1995-02-01 ZA ZA95776A patent/ZA95776B/en unknown
- 1995-02-02 IL IL11252195A patent/IL112521A/en not_active IP Right Cessation
- 1995-02-09 TW TW084101235A patent/TW436296B/en active
-
1996
- 1996-08-01 BG BG100763A patent/BG62843B1/en unknown
- 1996-08-01 FI FI963051A patent/FI118205B/en not_active IP Right Cessation
- 1996-08-02 OA OA60873A patent/OA10446A/en unknown
- 1996-08-02 NO NO963244A patent/NO307954B1/en not_active IP Right Cessation
-
1999
- 1999-04-30 GR GR990401213T patent/GR3030131T3/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4007196A (en) * | 1973-01-30 | 1977-02-08 | A/S Ferrosan | 4-Phenylpiperidine compounds |
| WO1991013612A1 (en) * | 1990-03-12 | 1991-09-19 | Beecham Group Plc | Composition |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP536A (en) | Oral liquid compositions containing paroxetine resinate | |
| US20030083354A1 (en) | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions | |
| AU2003216399A1 (en) | Diphenhydramine tannate liquid and semi-solid compositions and methods of use | |
| JPH02111719A (en) | drug adsorbate | |
| CZ291231B6 (en) | Pharmaceutical formulation comprising mycophenolate mofetil or mycophenolic acid and process for preparing thereof | |
| NZ534746A (en) | Palatable oral suspension and method | |
| ZA200201709B (en) | Quetiapine granules. | |
| US20080125453A1 (en) | Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions | |
| JP3051459B2 (en) | Pharmaceutical preparations for oral administration in fluid form | |
| KR101683293B1 (en) | Composition for oral use | |
| CA2399411A1 (en) | Water dispersible formulation of paroxetine | |
| EP1628656B1 (en) | Gabapentin tannate in liquid and/or semi-solid dosage forms | |
| JP4138209B2 (en) | Pravastatin-containing composition | |
| HK1012288B (en) | Oral liquid compositions containing paroxetine resinate |